About Metastatic Prostate Cancer
Metastatic prostate cancer (mPC) occurs when prostate cancer cells spread beyond the prostate gland to distant sites, most commonly the bones, lymph nodes, and less frequently to the liver, lungs, or brain. Prostate cancer is the second most common cancer in men worldwide and the fifth leading cause of cancer death.
The disease exists on a spectrum from hormone-sensitive (mHSPC) — where the cancer still responds to androgen deprivation therapy — to castration-resistant (mCRPC), where the cancer progresses despite testosterone suppression. The transition from hormone-sensitive to castration-resistant disease marks a critical inflection point in prognosis and treatment approach.
Advances in treatment over the past decade have significantly improved outcomes. The CHAARTED and LATITUDE trials demonstrated that adding docetaxel or abiraterone to standard androgen deprivation therapy in newly diagnosed metastatic disease substantially extends survival, particularly in high-volume disease.
Staging & Classification
Metastatic prostate cancer staging uses the TNM (Tumor, Node, Metastasis) system, with Stage IV indicating distant metastases:
| Stage | Definition | Sites |
|---|---|---|
| M1a | Non-regional lymph node metastases | Para-aortic, mediastinal, cervical nodes |
| M1b | Bone metastases | Spine, pelvis, ribs, long bones (most common) |
| M1c | Other visceral metastases | Liver, lungs, brain, adrenal glands |
Disease volume classification (from CHAARTED trial) is also critical for treatment decisions:
| Volume | Definition | Prognosis Impact |
|---|---|---|
| Low volume | <4 bone metastases and no visceral metastases | Better prognosis, median OS ~50–55 months with combination therapy |
| High volume | ≥4 bone metastases (with ≥1 beyond axial skeleton) OR visceral metastases | Worse prognosis, median OS ~35–40 months with combination therapy |
Risk Group Stratification
Prognostic risk stratification integrates multiple factors to estimate outcomes and guide treatment intensity:
| Risk Group | Characteristics | Estimated Median Survival |
|---|---|---|
| Low Risk | Gleason ≤7, PSA <20 ng/mL, few bone metastases (≤3), no visceral metastases, ECOG 0–1 | 4–6+ years |
| Intermediate Risk | Mixed features (e.g., Gleason 7 with moderate disease volume, or Gleason 8 with limited metastases) | 2.5–4 years |
| High Risk | Gleason ≥8, PSA >100 ng/mL, extensive bone metastases (>10), visceral metastases, ECOG ≥2 | 1–2.5 years |
Important: These are statistical estimates based on population data. Individual outcomes vary widely based on response to treatment, molecular characteristics, and other patient-specific factors. Modern combination therapies have improved survival significantly compared to historical data.
Prognostic Factors Diagram
Gleason Score & Grade Groups
The Gleason grading system, originally developed in the 1960s by Dr. Donald Gleason, is the primary histological grading system for prostate cancer. It is based on the microscopic architectural pattern of the tumor. In 2014, the International Society of Urological Pathology (ISUP) introduced Grade Groups to simplify and improve prognostic stratification:
| Gleason Score | Grade Group | Pattern | Prognostic Significance |
|---|---|---|---|
| 6 (3+3) | 1 | Well-differentiated | Very favorable; indolent behavior |
| 7 (3+4) | 2 | Predominantly well-differentiated | Favorable; intermediate prognosis |
| 7 (4+3) | 3 | Predominantly poorly differentiated | Intermediate; worse than 3+4 |
| 8 (4+4, 3+5, 5+3) | 4 | Poorly differentiated | Unfavorable; aggressive behavior |
| 9–10 (4+5, 5+4, 5+5) | 5 | Very poorly differentiated | Very unfavorable; highly aggressive |
Treatment Options
Treatment of metastatic prostate cancer is guided by disease volume, risk stratification, hormone sensitivity, and patient fitness:
- Androgen Deprivation Therapy (ADT): The backbone of metastatic prostate cancer treatment. Medical castration with GnRH agonists (leuprolide, goserelin) or antagonists (degarelix, relugolix) suppresses testosterone to castrate levels (<50 ng/dL).
- ADT + Docetaxel: For newly diagnosed high-volume mHSPC (CHAARTED/STAMPEDE trials). Six cycles of docetaxel added to ADT improved median overall survival by 13–17 months in high-volume disease.
- ADT + Novel Hormonal Agents: Abiraterone acetate + prednisone, enzalutamide, apalutamide, or darolutamide added to ADT for mHSPC. These agents improve survival across volume categories.
- ADT + Triplet Therapy: The PEACE-1 and ARASENS trials showed that adding both a novel hormonal agent and docetaxel to ADT (triplet therapy) improves outcomes in high-volume disease.
- Radiation to primary tumor: The STAMPEDE trial showed improved survival with prostate radiation in low-volume metastatic disease.
- For mCRPC: Options include second-line hormonal agents, taxane chemotherapy (cabazitaxel), PARP inhibitors (for BRCA/HRR-mutated tumors), radium-223 (for symptomatic bone metastases), and lutetium-177 PSMA (for PSMA-positive disease).
Prognosis Factors
Multiple factors influence prognosis in metastatic prostate cancer:
- Favorable factors: Lower Gleason score (≤7), lower PSA (<20 ng/mL), bone-only metastases, few metastatic sites, good performance status (ECOG 0–1), normal alkaline phosphatase and LDH, absence of pain
- Unfavorable factors: Higher Gleason score (≥8), very high PSA (>100 ng/mL), visceral metastases (especially liver), extensive bone disease (>10 lesions), poor performance status (ECOG ≥2), elevated alkaline phosphatase and LDH, rapid PSA doubling time
- Molecular markers: Genomic alterations in BRCA1/2, ATM, and other homologous recombination repair (HRR) genes may predict response to PARP inhibitors. Mismatch repair deficiency (MSI-high) may predict response to immunotherapy.
- Response to initial therapy: Depth and duration of PSA response to initial treatment is a strong predictor of long-term outcomes. A PSA nadir <0.2 ng/mL after initial treatment is associated with significantly longer survival.
Frequently Asked Questions
What is the life expectancy with metastatic prostate cancer?
Life expectancy varies widely depending on the factors described above. With modern combination therapies, median survival for metastatic hormone-sensitive prostate cancer ranges from approximately 4–6+ years for low-volume disease to 3–4 years for high-volume disease. For metastatic castration-resistant prostate cancer, median survival ranges from 1–3 years depending on risk factors and treatment response. Individual outcomes can be substantially better or worse than these averages.
What does the Gleason score mean?
The Gleason score reflects how abnormal the cancer cells look under a microscope. It ranges from 6 (least aggressive, well-differentiated) to 10 (most aggressive, poorly differentiated). The score is the sum of the two most prevalent growth patterns (each graded 1–5). Higher scores indicate more aggressive cancer with worse prognosis. In the context of metastatic disease, Gleason 8–10 tumors are associated with more aggressive behavior and shorter survival.
Can metastatic prostate cancer be cured?
While metastatic prostate cancer is generally considered incurable with current therapies, many patients achieve long-term disease control. Some patients with oligometastatic disease (limited number of metastases) may achieve durable remissions with aggressive local treatments (surgery, radiation) combined with systemic therapy. The concept of "cure" is evolving as treatments improve and some patients survive 10+ years with metastatic disease.
What is the ECOG performance status?
ECOG (Eastern Cooperative Oncology Group) performance status is a standardized scale from 0 to 4 that measures how a patient's disease affects their daily living abilities. ECOG 0 means fully active with no restrictions; ECOG 1 means restricted in strenuous activity but ambulatory; ECOG 2 means ambulatory but unable to work; ECOG 3 means limited self-care; ECOG 4 means completely disabled. Performance status is one of the strongest predictors of treatment tolerance and survival in oncology.